Klepzig M, Kleinhans E, Büll U, Strauer B E
Z Kardiol. 1985 Feb;74(2):85-90.
The purpose of this study was to evaluate acute and chronic therapeutic effects of the positive inotropic vasodilating agent amrinone. 50 patients with cardiomyopathy or coronary artery disease and left heart failure participated in the study. Swan-Ganz catheterisation was used in 15 patients; following injection of 1.5 mg/kg amrinone, the mean pulmonary pressure decreased by 26%, the wedge pressure by 27%. Cardiac index rose by 18% (p less than 0.01). 35 patients were examined in the oral study, the avg. dose being 300 mg/day. After 2 and 12 weeks of therapy, exercise tolerance increased by 22% and 13% respectively (p less than 0.05). Cardiac output after maximal workload as determined by equilibrium radionuclide ventriculography increased by 27% and 30% respectively (p less than 0.05). 34 side effects occurred in 23 of 35 patients: nausea, orthostasis, angina pectoris, tachyarrhythmia, hepatotoxicity, thrombocytopenia, hyperuricemia and brown coloring of finger-nails. From the hemodynamic point of view amrinone is intravenously and orally effective. Careful selection of patients and frequent examinations are however necessary.
本研究的目的是评估正性肌力血管扩张剂氨力农的急慢性治疗效果。50例患有心肌病或冠状动脉疾病并伴有左心衰竭的患者参与了该研究。15例患者使用了 Swan-Ganz 导管插入术；注射1.5mg/kg氨力农后，平均肺动脉压下降了26%，楔压下降了27%。心脏指数上升了18%（p<0.01）。35例患者进行了口服研究，平均剂量为300mg/天。治疗2周和12周后，运动耐量分别提高了22%和13%（p<0.05）。通过平衡放射性核素心室造影确定的最大工作量后的心输出量分别增加了27%和30%（p<0.05）。35例患者中有23例出现了34种副作用：恶心、直立性低血压、心绞痛、快速性心律失常、肝毒性、血小板减少、高尿酸血症和指甲变色。从血液动力学角度来看，氨力农静脉注射和口服均有效。然而，需要仔细挑选患者并进行频繁检查。
